{
    "2016-02-22": [
        "Dowling & Yahnke LLC Sells 87 Shares of Amgen, Inc. AMGN",
        "Amgen: A Biiotech Buy & Hold Story AMGN",
        "RBC AMGN Positive new incremental growth driver: Phase III \"Romo\" bone data shows high efficacy,suggests $1B+ franchise",
        "Not sure what to do with AMGN? Explore our fundamental pros and cons"
    ]
}